Remdesivir Market Report 2025

This Remdesivir market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The remdesivir market size has grown exponentially in recent years. It will grow from $6.49 billion in 2024 to $8.52 billion in 2025 at a compound annual growth rate (CAGR) of 31.2%. The growth in the historic period can be attributed to increasing prevalence of COVID-19, rising awareness of remdesivir, government support for remdesivir, clinical trials and research, government purchases.

The remdesivir market size is expected to see rapid growth in the next few years. It will grow to $15.91 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to ongoing COVID-19 response, emerging variants, global vaccination campaigns, pandemic preparedness, global health initiatives. Major trends in the forecast period include personalized medicine, combination therapies, production scalability, telemedicine and remote monitoring, research on new indications, alternative antiviral therapies.

Rising government expenditure is anticipated to drive the expansion of the remdesivir market. This form of spending, encompassing funds directed by the government toward operations, programs, and services, plays a pivotal role in fostering the accessibility and growth of Remdesivir, particularly in times of public health crises. By allocating resources, providing regulatory support, and investing in research, governments contribute significantly to enhancing the availability and affordability of this critical antiviral medication. For instance, in July 2023, the UK government increased its spending on services and capital projects, thereby contributing to the market's growth.

The escalating demand for clinical trials and research is poised to fuel the remdesivir market. These systematic investigations in healthcare evaluate the safety and efficacy of medical interventions, including Remdesivir's effectiveness in treating viral infections like COVID-19. These trials yield vital scientific evidence regarding the drug's impact on symptom severity, duration, and safety. For instance, as of May 2023, there has been a notable increase in registered clinical studies, indicating a growing need for research and trials. This surge in demand underscores the driving force behind the market's growth.

Major companies in the remdesivir market are obtaining FDA approvals for new drugs, such as Veklury (Remdesivir), to bolster their market position. Veklury, approved by the FDA in January 2022, serves as an antiviral medication specifically designed to treat mild to moderate COVID-19 symptoms in adults and children. This strategic move by companies like Gilead Sciences Inc. contributes to their profitability and market dominance.

Leading companies in the remdesivir market are forming partnerships to enhance their profitability. For example, in July 2022, Gilead Sciences, a US-based biopharmaceutical company focused on antiviral therapies, entered into a new joint procurement agreement with the European Commission. This partnership was intended to optimize the distribution of its antiviral treatments, including Remdesivir, to European member states, ensuring that essential medications are delivered in a timely manner. The European Commission serves as the executive body of the European Union and is based in Belgium.

In February 2023, Kite Pharma, a US-based biotechnology firm, completed the acquisition of Tmunity Therapeutics Inc for an undisclosed sum. This strategic move is aimed at granting Kite access to a range of pre-clinical and clinical initiatives, as well as efficient production techniques. Notably, the acquisition includes access to Tmunity's 'armored' CAR T technology platform, which holds promise for enhancing the effectiveness of various CAR T therapies against tumors.

Remdesivir, classified as an antiviral drug, is utilized in the treatment of hospitalized adults and children aged 28 days and older, weighing at least 6.6 pounds, for the management of COVID-19 disease 2019 (COVID-19) caused by the SARS-CoV-2 virus. It is specifically recommended for individuals at significant risk of developing severe COVID-19, potentially leading to hospitalization or fatal outcomes.

The primary routes of administering remdesivir are oral and intravenous. Intravenous administration involves delivering the drug or substance directly into a vein using a syringe or tubing. Remdesivir is available in various dosage forms such as tablets, frozen solutions, and lyophilized solutions. These medications are distributed through diverse channels including hospitals, clinics, drug stores or pharmacies, online platforms, and other relevant healthcare avenues.

The remdesivir market research report is one of a series of new reports that provides remdesivir market statistics, including remdesivir industry global market size, regional shares, competitors with a remdesivir market share, detailed remdesivir market segments, market trends and opportunities, and any further data you may need to thrive in the remdesivir industry. This Remdesivir market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the remdesivir market include Gilead Sciences Inc., BrightGene Bio-Medical Technology Co Ltd, Hainan Haiyao Co. Ltd., Sichuan Kelun Pharmaceutical Co. Ltd., Hunan Warrant Pharmaceutical, Cipla Limited, Pfizer Inc., Merck & Co. Inc., Cayman Chemical Company, Dr Reddy’s Laboratories Ltd., Inovio Pharmaceuticals, Shenzhen BORUI Pharmaceutical Technology Co. Ltd., Berry Global Group, Hetero Labs Limited, Mylan N.V., Zydus Cadila Health Care Limited, Syngene International Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Teva Pharmaceutical Industries, Ferozsons Laboratories Limited, Jubilant Life Sciences, Laurus Labs, Macleods Pharmaceuticals, Natco Pharma, Sandoz Group AG, Strides Pharma Science Limited, Torrent Pharmaceuticals, Beximco Pharmaceuticals Ltd., Fresenius Kabi, Gland Pharma Limited, Hikma Pharmaceuticals, Lark Laboratories.

North America was the largest region in the remdesivir market in 2024. Middle East is expected to be the fastest growing region in the remdesivir market report during the forecast period. The regions covered in the remdesivir market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the remdesivir market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The remdesivir market consists of sales of nucleotide analogue and Veklury. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.